February 2010

Northern California Melanoma Center
St. Mary's Medical Center, 6th Floor
450 Stanyan Street
San Francisco, CA 94117-1079

tel: 415.750.5660
fax: 415.750.4860
email: ncmc@chw.edu
web: http://www.melanomacenter.com

Adjuvant
Studies for patients who are clinically free of disease but at high risk for recurrence. These often involve agents aimed at boosting the immune responses. NOTE: to be eligible for these trials, patients must start therapy within 8 weeks of surgical excision of the lymph nodes. Therefore, it is important that you contact us as soon as possible before or after your surgery to allow the screening studies to be done and therapy started within this time-frame.

Metastatic Disease
First-Line: Studies for patients with metastatic melanoma that cannot be surgically excised or treated by other means, such as radiation therapy. These studies are limited to patients who have not had prior chemotherapy.

First- or Second-Line: Studies for patients with metastatic melanoma who have had prior chemotherapy and experienced disease progression.

Follow-on: Study for patients whose melanoma has responded to systemic treatment. Treatment under this study is aimed at consolidating and maintaining the remission.

Other:

• An Exploratory Analysis of Tumor Specific T Cells in Subjects with Clinically and Histologically Diagnosed Cancer

Melanoma Center Active Clinical Trials - February 2010 Summary Sheet PDF